| | 90098-04-7 Basic information More.. |
| Product Name: | Rebamipide | | Synonyms: | (+-)-1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-4-quinolinepropanoica;(+-)-2-(4-chlorobenzoylamino)-3-(2(1h)-quinolinon-4-yl)propionicacid;Mucosta;Proamipide;2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo- (+-)-4-quinolinepropanoic acid;2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-quinolyl)propionic acid;2-(4-CHLOROBENZAMIDO)-3-(2-OXO-1,2-DIHYDROQUINOLIN-4-YL)PROPANOIC ACID;OPC-12759, Mucosta, α-[(4-Chlorobenzoyl)-amino]-1,2-dihydro-2-oxo-4-quinolinepropanoic Acid | | CAS: | 90098-04-7 | | MF: | C19H15ClN2O4 | | MW: | 370.79 | | EINECS: | 1308068-626-2 | | Mol File: | 90098-04-7.mol |  |
Use
Rebamipide, a gastroprotective drug, was developed in Japan and was proven to be superior to cetraxate, the former most prescribed drug of the same category, in 1989 in the treatment for gastric ulcers. The initially discovered basic mechanisms of action of rebamipide included its action as a prostaglandin inducer and oxygen free-radical scavenger. In the last 5 years, several basic and clinical studies have been performed for functional dyspepsia, chronic gastritis, NSAID-induced gastrointestinal injuries, gastric ulcer following eradication therapy for Helicobacter pylori, gastric ulcer after endoscopic surgery and ulcerative colitis. In addition, several molecules have been identified as therapeutic targets of rebamipide to explain its pleiotropic pharmacological actions.
- Rebamipide
-
- US $0.00-0.00 / kg
- 2026-04-23
- CAS:90098-04-7
- Min. Order: 1kg
- Purity: 99%min
- Supply Ability: 5000kg
- Rebamipide
-
- 2026-04-22
- CAS:90098-04-7
- Min. Order:
- Purity: 0.99
- Supply Ability:
- Rebamipide
-
- US $33.00 / g
- 2026-04-22
- CAS:90098-04-7
- Min. Order:
- Purity: 99.54%
- Supply Ability: 10g
|
|
90098-04-7
Recommend Suppliers |
|